Iovance Biotherapeutics, Inc. · NASDAQ:IOVA

Iovance Biotherapeutics — Investor Presentation (August 2026)

34 slides from Iovance Biotherapeutics's investor presentation, Aug 6, 2026

  1. Slide 1: Corporate Overview August 2026

    1 © 2026, Iovance Biotherapeutics, Inc. Corporate Overview August 2026 1

  2. Slide 2: Forward-Looking Statements

    2 © 2026, Iovance Biotherapeutics, Inc. Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation

  3. Slide 3: Global Leader in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer

    3 © 2026, Iovance Biotherapeutics, Inc. Global Leader in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer Approved Products Commercial Launch Financials >95 Treatment Centers as of 08/05/26* 2 >95% Margin from Cost of Sales1 56% © 2026, Iovance Biotherapeutics, Inc. *Includ

  4. Slide 4: The Pioneer in One-Time Cell Therapy for Solid Tumors

    4 © 2026, Iovance Biotherapeutics, Inc. The Pioneer in One-Time Cell Therapy for Solid Tumors © 2026, Iovance Biotherapeutics, Inc. 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population; 2. Karapetyan L et al. Transplantation & Cell Therapy 2026. Physician-asses

  5. Slide 5: Strong Platform Supports Backbone IO Therapy for Solid Tumors

    5 © 2026, Iovance Biotherapeutics, Inc. Strong Platform Supports Backbone IO Therapy for Solid Tumors Iovance Retains Global Portfolio and Technology Platform Rights Abbreviations: 2L, second line; 4L, fourth line; CRC, colorectal cancer; DDLPS, dedifferentiated liposarcoma; ER, estrogen-receptor; F

  6. Slide 6: Significant U.S. Commercial Business Growth and Progress in Global Expansion

    6 © 2026, Iovance Biotherapeutics, Inc. Significant U.S. Commercial Business Growth and Progress in Global Expansion

  7. Slide 7: Significant Unmet Need in Frontline and Beyond

    7 © 2026, Iovance Biotherapeutics, Inc. Significant Unmet Need in Frontline and Beyond1 Advanced Melanoma Market Opportunity 2L+ Advanced Melanoma Population2,3 US: 8.5K Potential ex-US Markets: 22K Overall (1L+): 70K BRAF wild-type (prior ICI therapy) ~5 months BRAF mutated (prior ICI and targeted

  8. Slide 8: One Third of Responses Remain Ongoing without Subsequent Treatment

    8 © 2026, Iovance Biotherapeutics, Inc. One Third of Responses Remain Ongoing without Subsequent Treatment 5-Year OS 19.7% mDOR 36.5 Months ORR 31.4% mOS 13.9 Months 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre-Treated Patient Population Abbreviations: mDOR, median duration of re

  9. Slide 9: Best-in-class real-world data driving increased Amtagvi adoption

    9 © 2026, Iovance Biotherapeutics, Inc. 52% ORR(12/23) OS Not Reached Best-in-class real-world data driving increased Amtagvi adoption1 1. Karapetyan L et al. Transplantation & Cell Therapy 2026 2. Three Prior Lines of Therapy (1L-3L): 1L ipilimumab + nivolumab; 2L dabrafenib + trametinib; 3L nivolu

  10. Slide 10: One Shared Infrastructure with Scalable Expansion

    10 © 2026, Iovance Biotherapeutics, Inc. One Shared Infrastructure with Scalable Expansion Melanoma Medical Oncologist Currently Treating NSCLC Medical Oncologist Educating Sarcoma Medical Oncologist Educating Endometrial Medical Oncologist Educating One-Time Treatment 11 Patient Identification 22 T

  11. Slide 11: Manufacturing Facility Dedicated to Global Delivery of Commercial and Clinical TIL Cell Therapies

    11 © 2026, Iovance Biotherapeutics, Inc. • The only scaled, centralized FDA-approved commercial TIL manufacturing process • Continually improving end-to-end commercial turnaround (~31 days) • Modular design • 5K+ patient annual capacity • Optimal utilization, quality & COS Manufacturing Facility Ded

  12. Slide 12: Amtagvi Authorized Treatment Centers (ATC)

    12 © 2026, Iovance Biotherapeutics, Inc. >95 ATCs in North America1,2 1/3 in Community Setting ≤100 10K+ Population2 1. Not all authorized treatment centers are listed. Includes onboarded ATCs as well as in-process ATCs. 2. U.S. Census Bureau, 2024 Annual Estimates. SEER annual estimated death rate

  13. Slide 13: Broad Amtagvi U.S. Market and Geographic Access

    13 © 2026, Iovance Biotherapeutics, Inc. Broad Amtagvi U.S. Market and Geographic Access Data on file as of August 2026. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: NCCN, National Comprehensive Cancer Network Lives covered; majority with private c

  14. Slide 14: Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors

    14 © 2026, Iovance Biotherapeutics, Inc. Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors 1. Amtagvi USPI Circulation Infused TIL circulate in the blood Migration to Tumor Recognition Lysis TIL expansion T cells grown to the billions1 Tumor collection Tumor resect

  15. Slide 15: Deep Pipeline of Registrational Programs

    15 © 2026, Iovance Biotherapeutics, Inc. Deep Pipeline of Registrational Programs

  16. Slide 16: Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma

    16 © 2026, Iovance Biotherapeutics, Inc. Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma • mPFS and mDOR not reached at ~2 years of median follow up (21.7 months) • All response-evaluable patients demonstrated regression of target lesions • Safety consistent with u

  17. Slide 17: TILVANCE-301 Global Phase 3 and Confirmatory Trial

    17 © 2026, Iovance Biotherapeutics, Inc. Option to crossover to lifileucel after BIRC-confirmed PD 1:1 Randomization TILVANCE-301 Global Phase 3 and Confirmatory Trial *Pembrolizumab in both arms is started at the same time after randomization. Abbreviations: BIRC, blinded independent review committ

  18. Slide 18: Significant Unmet Need in 2L Nonsquamous NSCLC

    18 © 2026, Iovance Biotherapeutics, Inc. 1M+ Global Annual Deaths1 Significant Unmet Need in 2L Nonsquamous NSCLC – Limited durability with SOC Chemo (Docetaxel)2 12.8% ORR 5.6 mo mDOR 12.3 mo OS >90K Annual Deaths1 1. Data on file as of August 2026, includes targeted patient population (nonsquamous

  19. Slide 19: IOV-LUN-202 Registrational Trial Design

    19 © 2026, Iovance Biotherapeutics, Inc. IOV-LUN-202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel in Post-Anti-PD-1 NSCLC (NCT04614103) Abbreviations: Anti-PD-1, anti-programmed cell death inhibitor; IRC, independent review committee; NSCLC, non-small cell lung cancer; ORR, ob

  20. Slide 20: FDA Fast Track Designation in Second-Line Nonsquamous mNSCLC

    20 © 2026, Iovance Biotherapeutics, Inc. FDA Fast Track Designation in Second-Line Nonsquamous mNSCLC 1.Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback in melanoma. Patients progressed on or after chemotherapy and anti-PD-1 ther

  21. Slide 21: Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC

    21 © 2026, Iovance Biotherapeutics, Inc. Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC1 % Change from Baseline Time (Months) Since TIL Infusion PD-L1 Negative, EGFRWT Subgroup has a High Unmet Need2 Best Percentage Change from Baseline in Target Lesion SOD 64.3% ORR EGFRWT Time to

  22. Slide 22: Significant Market Opportunity for Advanced Soft Tissue Sarcomas

    22 © 2026, Iovance Biotherapeutics, Inc. 1. CancerMPact Patient Metrics for US Soft Tissue Sarcoma (accessed February 2026); 2. Zhou et al. BMC Public Health 2025; 3. CancerMPact Treatment Architecture for Sarcoma for the US & EU5 (May 2025) to inform treatment rates in the US and EU5. 4. Parikh RC,

  23. Slide 23: SARATOGA (IOV-SAR-201) Registrational Trial

    23 © 2026, Iovance Biotherapeutics, Inc. SARATOGA (IOV-SAR-201) Registrational Trial Phase 2 Multicenter Study of Lifileucel in Advanced Soft Tissue Sarcomas (NCT07741877) Abbreviations: CR, complete response; DCR, disease control rate; DOR, duration of response; IRC, independent review committee; N

  24. Slide 24: Strong Initial Data for Serous Advanced Endometrial Cancer

    24 © 2026, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2026 Estimates. https://seer.cancer.gov (accessed June 2026); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; 3. NCCN Guide

  25. Slide 25: IOV-END-201 Phase 2 Proof of Concept Study in Endometrial Cancer

    25 © 2026, Iovance Biotherapeutics, Inc. pMMR Subgroup* dMMR Subgroup* Endpoints • Primary: ORR per RECIST v1.1 by investigator • Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability IOV-END-201 Phase 2 Proof of Concept Study Endometrial Cancer Patient Population Recurrent, metastatic or p

  26. Slide 26: First-in-class Immuno-Oncology Technologies Target New Indications

    26 © 2026, Iovance Biotherapeutics, Inc. First-in-class Immuno-Oncology Technologies Target New Indications

  27. Slide 27: IOV-4001: PD-1 Inactivated TIL Therapy

    27 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. IOV-4001: PD-1 Inactivated TIL Therapy 2 T cell PD-1 PD-1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD-1, a checkpoint receptor that is activated by proteins (PD-L1

  28. Slide 28: Phase 1/2 First-in-Human Study: IOV-GM1-201

    28 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open-Label First-in-Human Study: IOV-GM1-201 Endpoints • Phase 1: Safety (Complete) • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD-1 Inactivated TIL Th

  29. Slide 29: IOV-3001: Next Generation IL-2 for TIL Supportive Regimen

    29 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. IOV-3001: Next Generation IL-2 for TIL Supportive Regimen1,2 Phase 1/2 trial enrolling patients Recombinant fusion protein designed to enhance TIL survival and cellular proliferation • A modified copy of the coding sequen

  30. Slide 30: IOV-5001: IL-12 Tethered TIL Therapy

    30 © 2026, Iovance Biotherapeutics, Inc. IOV-5001: IL-12 Tethered TIL Therapy 1. Zhang L, et al, Clin Cancer Res 2015;21(10):2278–2288; 2. Zhang L, et al, J Immunother Cancer 2020;8:e000210; 3. Kobayashi M, et al, J Exp Med 1989;170:827–845; 4. Zeh HJ, et al, J Immunother 1993;14:155–61; 5. Tugues S

  31. Slide 31: Phase 1/2 First-in-Human Study: IOV-GE1-201

    31 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open-Label First-in-Human Study: IOV-GE1-201 Endpoints • Phase 1: Safety • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary: CR rate, DOR, DCR, PFS, OS, safety and tolerability Genetically Engineered, IL-12 Tethered TIL Therapy IOV-5

  32. Slide 32: Financial Summary

    32 © 2026, Iovance Biotherapeutics, Inc. Financial Summary

  33. Slide 33: Financial Position & Outlook

    33 © 2026, Iovance Biotherapeutics, Inc. 1. Excludes depreciation and amortization 2. Cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2026 Financial Position & Outlook Cash runway into 2H 2028 Revenue Growth | Margin Improvement | Cost Control Cash position2 ~$304M

  34. Slide 34: Thank You

    34 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Thank You

Iovance Biotherapeutics — Investor Presentation (August 2026) on 6ix